Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Up 8.2% – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price was up 8.2% during mid-day trading on Tuesday . The stock traded as high as $49.35 and last traded at $49.35. Approximately 1,000 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 4,571 shares. The stock had previously closed at $45.63.

Analyst Ratings Changes

Several research analysts recently issued reports on ZLDPF shares. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The firm has a market cap of $3.40 billion, a P/E ratio of 3.47 and a beta of 0.88. The firm has a 50-day simple moving average of $48.95 and a 200-day simple moving average of $64.75.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.The firm had revenue of $10.79 million during the quarter, compared to analyst estimates of $19.69 million. As a group, analysts forecast that Zealand Pharma A/S will post 2.51 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.